Chimeric alphavirus replicon particles
Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
1. A chimeric alphavirus particle, comprising:
RNA derived from one or more alphaviruses; and
a capsid protein, wherein said capsid protein is derived from two or more different alphaviruses.
2. A chimeric alphavirus particle comprising RNA derived from a first alphavirus and structural proteins, wherein said structural proteins comprise:
(a) a hybrid capsid protein having (i) an RNA binding domain derived from said first alphavirus and (ii) an envelope glycoprotein interaction domain derived from a second alphavirus which is different from the first alphavirus; and
(b) an envelope glycoprotein derived from said second alphavirus.
3. The chimeric alphavirus particle of claim 1 , comprising:
RNA derived from a first alphavirus; and
an envelope glycoprotein having (i) a cytoplasmic tail portion derived from said first alphavirus and (ii) at least 95% of the remaining portion derived from a second alphavirus, wherein the second alphavirus is different from the first alphavirus.
4. A chimeric alphavirus particle comprising
(1) RNA encoding one or more nonstructural proteins derived from a first alphavirus,
(2) a packaging signal derived from a second alphavirus different from said first alphavirus, wherein said packaging signal is inserted into a site selected from the group consisting of the junction of nsP3 with nsP4 and a deletion in a nonstructural protein gene;
(3) a capsid protein derived from said second alphavirus; and
(4) an envelope protein derived from an alphavirus different from said first alphavirus.
5. The chimeric alphavirus particle of claim 4 , wherein packaging signal is inserted into a carboxy terminal deletion in a nonstructural protein gene.
6. The chimeric alphavirus particle of claim 4 , wherein said envelope protein is derived from said second alphavirus.
7. The alphavirus particle of claim 1 , wherein said particle is a replicon particle and said RNA comprises, in 5′ to 3′ order
(i) a 5′ sequence required for nonstructural protein-mediated amplification,
(ii) a nucleotide sequence encoding alphavirus nonstructural proteins,
(iii) a means for expressing a heterologous nucleic acid,
(iv) the heterologous nucleic acid sequence, said heterologous nucleic acid sequence replacing an alphavirus structural protein gene,
(v) a 3′ sequence required for nonstructural protein-mediated amplification, and
(vi) a polyadenylate tract.
8. The alphavirus particle of claim 2 , wherein said particle is a replicon particle and said RNA comprises, in 5′ to 3′ order
(i) a 5′ sequence required for nonstructural protein-mediated amplification,
(ii) a nucleotide sequence encoding alphavirus nonstructural proteins,
(iii) a means for expressing a heterologous nucleic acid,
(iv) the heterologous nucleic acid sequence, said heterologous nucleic acid sequence replacing an alphavirus structural protein gene,
(v) a 3′ sequence required for nonstructural protein-mediated amplification, and
(vi) a polyadenylate tract.
9. An alphavirus particle of claim 3 , wherein said particle is a replicon particle and said RNA comprises, in 5′ to 3′ order
(i) a 5′ sequence required for nonstructural protein-mediated amplification,
(ii) a nucleotide sequence encoding alphavirus nonstructural proteins,
(iii) a means for expressing a heterologous nucleic acid,
(iv) the heterologous nucleic acid sequence, said heterologous nucleic acid sequence replacing an alphavirus structural protein gene,
(v) a 3′ sequence required for nonstructural protein-mediated amplification, and
(vi) a polyadenylate tract.
10. An alphavirus particle of claim 4 , wherein said particle is a replicon particle and said RNA comprises, in 5′ to 3′ order
(i) a 5′ sequence required for nonstructural protein-mediated amplification,
(ii) a nucleotide sequence encoding alphavirus nonstructural proteins,
(iii) a means for expressing a heterologous nucleic acid,
(iv) the heterologous nucleic acid sequence, said heterologous nucleic acid sequence replacing an alphavirus structural protein gene,
(v) a 3′ sequence required for nonstructural protein-mediated amplification, and
(vi) a polyadenylate tract.
11. The chimeric alphavirus particle of claim 1 , wherein one of said two or more alphaviruses is Sindbis virus (SIN) and wherein another of said two or more alphaviruses is Venezuelan equine encephalitis virus (VEE).
12. The chimeric alphavirus particle of claim 1 , wherein one of said one or more alphaviruses is VEE and wherein one of said two or more alphaviruses is SIN.
13. The chimeric alphavirus particle of claim 2 , wherein said first alphavirus is SIN and wherein said second alphavirus is VEE.
14. The chimeric alphavirus particle of claim 2 , wherein said first alphavirus is VEE and wherein said second alphavirus is SIN.
15. The chimeric alphavirus particle of claim 3 , wherein said first alphavirus is SIN and wherein said second alphavirus is VEE.
16. The chimeric alphavirus particle of claim 3 , wherein said first alphavinis is VEE and wherein said second alphavirus is SIN.
17. The chimeric alphavirus particle of claim 4 , wherein said first alphavinis is SIN and wherein said second alphavirus is VEE.
18. The chimeric alphavirus particle of claim 4 , wherein said first alphavinis is VEE and wherein said second alphavirus is SIN.
19. The chimeric alphavirus particle of claim 7 , wherein one of said two or more alphaviruses is SIN and wherein another of said two or more alphaviruses is VEE.
20. The chimeric alphavirus particle of claim 7 , wherein one of said two or more alphaviruses is VEE and wherein one of said two or more alphaviruses is SIN.
21. The chimeric alphavirus particle of claim 8 , wherein said first alphavirus is SIN and wherein said second alphavirus is VEE.
22. The chimeric alphavirus particle of claim 8 , wherein said first alphavirus is VEE and wherein said second alphavirus is SIN.
23. The chimeric alphavirus particle of claim 9 , wherein said first alphavirus is SIN and wherein said second alphavirus is VEE.
24. The chimeric alphavirus particle of claim 9 , wherein said first alphavirus is VEE and wherein said second alphavirus is SIN.
25. The chimeric alphavirus particle of claim 10 , wherein said first alphavirus is SIN and wherein said second alphavirus is VEE.
26. The chimeric alphavirus particle of claim 10 , wherein said first alphavirus is VEE and wherein said second alphavirus is SIN.
27. The alphavirus particle of claim 1 , wherein said RNA further comprises a heterologous nucleic acid sequence.
28. The alphavirus particle of claim 27 , wherein said heterologous nucleic acid replaces at least one alphavirus structural protein.
29. The alphavirus replicon particle of claim 27 , wherein heterologous nucleic acid sequence encodes for a therapeutic agent or an immunogen.
30. A method for producing alphavirus replicon particles, comprising introducing into a host cell:
a) an alphavirus replicon RNA derived from one or more alphaviruses, wherein said replicon RNA further comprises one or more heterologous sequence(s); and
b) at least one separate defective helper RNA(s) encoding structural protein(s) absent from the replicon RNA, wherein one of said structural proteins is a capsid protein derived from two or more different alphaviruses,
wherein alphavirus replicon particles are produced.
31. The method of claim 30 , wherein said replicon RNA is derived from a first alphavirus and wherein said structural proteins comprise
(a) a hybrid capsid protein having (i) an RNA binding domain derived from said first alphavirus and (ii) an envelope glycoprotein interaction domain derived from a second alphavirus; and
(b) an envelope glycoprotein derived from said second alphavirus.
32. A method for producing alphavirus replicon particles, comprising introducing into a host cell:
a) an alphavirus replicon RNA encoding one or more nonstructural proteins from a first alphavirus, a packaging signal derived from a second alphavirus which is different from the first alphavirus, and one or more heterologous sequence(s), wherein said packaging signal is inserted into a site selected from the group consisting of the junction of nsP3 with nsP4 and a deletion in a nonstructural protein gene; and
b) at least one separate defective helper RNA(s) encoding structural protein(s) absent from the replicon RNA, wherein at least one of said structural proteins is a capsid protein derived from said second alphavirus, and at least one of said structural proteins is an envelope protein derived from an alphavirus different from said first alphavirus, wherein alphavirus replicon particles are produced.
33. A method of generating an immune response in a mammal, the method comprising administering a chimeric alphavirus particle of claim 29 to said mammal, thereby generating an immune response.
34. The chimeric alphavirus particle of claim 4 , wherein said RNA further comprises a heterologous nucleic acid sequence.
35. The chimeric alphavirus particle of claim 34 , wherein said heterologous nucleic acid sequences replaces at least one alphavirus structural protein.
36. The chimeric alphavirus particle of claim 34 , wherein said heterologous nucleic acid sequence encodes a therapeutic agent or an immunogen.
37. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 7 .
38. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 8 .
39. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 9 .
40. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 10 .
41. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 19 .
42. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 20 .
43. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 21 .
44. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 22 .
45. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 23 .
46. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 24 .
47. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 25 .
48. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 26 .
49. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 27 .
50. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 28 .
51. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 29 .
52. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 34 .
53. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 35 .
54. A method of generating an immune response in a mammal comprising administering to said mammal a chimeric alphavirus particle of claim 36 .
55. The method of claim 30 wherein the replicon RNA is derived from a first alphavirus and wherein said structural proteins comprise an envelope glycoprotein having (i) a cytoplasmic tail portion derived from the first alphavirus and (ii) at least 95% of the remaining portion derived from a second alphavirus, wherein the second alphavirus is different from the first alphavirus.